{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017880","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.136896+00:00","generated_at":"2026-06-15T22:25:48.092587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vir Biotech Q1 revenue $63M (down 95% YoY); net loss $140.9M; new CEO Marianne De Backer","bullets":["Q1 2023 total revenues $63M vs $1.2B in Q1 2022 (-94.9%); net loss of $140.9M ($1.06/sh) vs net income of $518.6M.","Cash, equivalents, and investments $2.3B at March 31; anticipates ~$272M payment to GSK in Q2 2023 for excess sotrovimab.","Marianne De Backer joined as CEO in April 2023; Sung Lee appointed EVP & CFO in March 2023.","Pipeline: Phase 2 data readouts for influenza (mid-2023), hepatitis B (2023), hepatitis D (H2 2023); $10M Gates Foundation grant for HIV vaccine trial.","R&D expenses rose to $157.6M (up 75% YoY) driven by VIR-2482 influenza antibody program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017880","json":"https://secwatch.observer/filing/0000950170-23-017880.json","markdown":"https://secwatch.observer/filing/0000950170-23-017880.md","text":"https://secwatch.observer/filing/0000950170-23-017880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/0000950170-23-017880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/vir-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:25:48.092587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86f0cb4edaa21a3d1f4b52692745e4136a89db48","claim":"Vir Biotechnology, Inc. reported first quarter ended March 31, 2023 results: revenue $63.0 million.","evidence_excerpt":"Total revenues for the quarter ended March 31, 2023, were $63.0 million compared to $1.2 billion for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/0000950170-23-017880-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$63.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}